Grace Therapeutics, Inc. (GRCE) stock
GRCENasdaqPharmaceutical PreparationsFiscal year ends March 31
$1.81−0.04 (-2.43%)
Close on Nov 12, 2026Market cap $38.08MP/E –Yield –
Grace Therapeutics gross margin
Gross margin is gross profit as a percentage of revenue.
Grace Therapeutics's gross margin for the twelve months ending Mar 31, 2022 was 100.0%. For fiscal 2022 it was 100.0%, against 61.2% the year before.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2022 | Mar 31, 2022 | 100.0% | +38.8 |
| FY2021 | Mar 31, 2021 | 61.2% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q4 FY2022CQ1 2022 | Mar 31, 2022 | 100.0% | – |
| Q4 FY2021CQ1 2021 | Mar 31, 2021 | 65.2% | – |
| Q3 FY2021CQ4 2020 | Dec 31, 2020 | 55.6% | – |
See a number that looks wrong?